Epeius Bio Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo : Tue, 25 Mar 2008 : California Newswire™

Home » CA Business, CA Medical, California NEWS INDEX, City: San Marino, Newsdesk

Epeius Bio Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo

Edited by Cindy Holden
published Tue, 25 Mar 2008 – 15:11:24 +0000 UTCNo Comment

SAN MARINO, Calif. — Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company’s leading anti-cancer agent, Rexin-G.

Administered clinically by simple intravenous infusion, the Epeius tumor-targeted gene delivery system enables Rexin-G to seek out and accumulate selectively in cancerous tissues and remote metastatic tumor nodules that have spread throughout the body. Rexin-G delivers it tumor-killing payload precisely where it is needed most, by targeting cancer from the inside.

Rexin-G demonstrates profound single agent efficacy in a broad spectrum of chemotherapy refractory cancers, including pancreatic cancer, breast cancer, colon cancer, squamous cell carcinoma of larynx, uterine cancer, gastric cancer, malignant melanoma, validating Epeius Biotechnologies’ in vivo targeted gene delivery platform (Int’l J Oncol, 2006, 2007).

The response rates seen with Rexin-G are unmatched by any other tumor-targeted gene delivery system. The U.S. FDA has granted Orphan Drug Status to Rexin-G based on its performance as a single therapeutic agent in treating chemotherapy refractory pancreatic cancer. Based on its exemplary record of safety and efficacy as an anti-cancer agent in a broad spectrum of chemo-resistant tumors, Rexin-G received accelerated approval for the treatment of all solid tumors by the Philippine BFAD, leading to its registration.

Currently, Rexin-G is being tested as a single therapeutic agent in three separate U.S. Phase I/II Trials for recurrent or metastatic cancers of the breast or pancreas and for bone and soft tissue sarcoma respectively. Additionally, a Phase II Registration Protocol is underway for chemo-resistant osteosarcoma in Los Angeles, California.

About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. Credited with innovations ranging from proto-oncogene discovery, designer therapeutics, pathotropic (disease-seeking) targeting, high-performance vector engineering, to advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to “launch” its enabling platform technologies for the benefit of cancer patients worldwide.

To learn more about Rexin-G(R) and the Epeius pipeline of proprietary biotechnologies currently available for licensing and clinical trials, please visit us at www.epeiusbiotech.com.

[tags]RexinG Trials for recurrent or metastatic cancers, Orphan Drug Status, Epeius Biotechnologies Corporation, chemotherapy refractory cancers[/tags]

ABOUT THE EDITOR: Cindy Holden has been an editor with the Neotrope News Network since 2004, which is a content partner with Send2Press® Newswire USA. She is a part time photographer, and was born and raised in California. She does NOT want Sarah Palin in the white house.